Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04809467
Title A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Incyte Corporation
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

B-cell lymphoma

marginal zone B-cell lymphoma

mantle cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Parsaclisib + Tafasitamab-cxix

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | BEL | AUT


No variant requirements are available.